MDMB-5'Br-BUTINACA (5'-Br-MDMB-BUTINACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug. It was first identified in Russia in August 2022. It is believed to be synthesized from the "half finished" synthesis precursor MDMB-5Br-INACA, which is shipped to the destination and then the final synthetic step is completed on arrival.[1][2][3]
 | |
| Identifiers | |
|---|---|
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C19H26BrN3O3 |
| Molar mass | 424.339 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
See also
editReferences
edit- ^ Cumyl-PeGaClone and other recently encountered synthetic cannabinoid receptor agonists. A review of the evidence on their use and harms. Advisory Council on the Misuse of Drugs, 2022
- ^ Yurchenko L, Pavlovets Y (August 2022). "Recent trends in the identification of psychoactive substances". Latest Trends in the Field of Identification of Psychoactive Substances (in Russian). 32. doi:10.13140/RG.2.2.34906.62402.
- ^ Deventer MH, Persson M, Norman C, Liu H, Connolly MJ, Daéid NN, McKenzie C, Gréen H, Stove CP (October 2023). "In vitro cannabinoid activity profiling of generic ban-evading brominated synthetic cannabinoid receptor agonists and their analogs". Drug Testing and Analysis. doi:10.1002/dta.3592. PMID 37903509. S2CID 264671035.
 | This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |